DXCM Maintains Buy Rating by BTIG -- Price Target Raised to $96.00

gurufocus.com · 2026-10-12

On October 12, 2026, BTIG analyst Ryan Zimmerman maintained a Buy rating on DexCom (DXCM) while raising the price target from $90.00 to $96.00, reflecting a 6.6

TickrTrends take: BTIG's maintained buy rating and raised price target of $96 align with TickrTrends' assessment that DXCM is currently undervalued in the Healthcare sector, suggesting analyst confidence in the company's fundamental prospects. A valuation-focused reader should monitor whether the stock price movement toward the $96 target occurs alongside earnings performance and whether the market eventually reprices the company to close any valuation gap that currently exists. The combination of sustained analyst support and an undervalued designation indicates potential for convergence between current trading levels and fair value.

Read the full story at gurufocus.com →